OPCML gene promoter methylation and gene expression in tumor and stroma cells of invasive cervical carcinoma

Cancer Investigation

Volumn 26, Issue 6, 2008, Pages 569-574

  Ye, Feng ^a   Zhang, Song Fa ^b   Xie, Xing ^a   Lu, Wei Guo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cervical carcinoma; Epigenetics; OPCML; Promoter methylation

Indexed keywords

ADULT; ARTICLE; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; OPCML GENE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ADULT; CARCINOMA; CELL ADHESION MOLECULES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; STROMAL CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 46349089120     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701837044     Document Type: Article

References (35)

1. Murthy, N.S.; Sehgal, A.; Satyanarayana, L.; Das, D.K.; Singh, V.; Das, B.C.; Gupta, M.M.; Mitra, A.B.; Luthra, U.K. Risk factors related to biological behavior of precancerous lesions of the uterine cervix. Br J Cancer 1990, 61, 732-736.
2. Ostor, A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993, 12, 186-192.
3. Zur Hausen, H.; Rosl, F. Pathogenesis of cancer of the cervix. Cold Spring Harbor Symp. Quant Biol 1994, 59, 623-628.
4. Knudson, A.G. Jr. Introduction to the genetics of primary renal tumors in children. Med Pediatr Oncol 1993, 21(3), 193-198.
5. Balmain, A.; Gray, J.; Ponder, B. The genetics and genomics of cancer. Nat Genet 2003, 33, Suppl: 238-244.
6. Shen, C.Y.; Yu, J.C.; Lo, Y.L.; Kuo, C.H.; Yue, C.T.; Jou, Y.S.; Huang, C.S.; Lung, J.C.; Wu, C.W. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000, 60, 3884-3892.
7. Davis, M.; Hitchcock, A.; Foulkes, W.D.; Campbell, I.G. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996, 56, 741-744.
8. Connolly, K.C.; Gabra, H.; Millwater, C.J.; Taylor, K.J.; Rabiasz, G.J.; Watson, J.E.; Smyth, J.F.; Wyllie, A.H.; Jodrell, DI.; Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer. Cancer Res 1999, 59, 2806-2809.
9. Kersemaekers, A.M.; van de Vijver, M.J.; Kenter, G.G. et al. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Gene Chrom Cancer 1999 Dec; 26(4), 346-354.
10. Hampton, G.M.; Penny, L.A.; Baergen, R.N.; Larson, A.; Brewer, C.; Liao, S.; Busby-Earle, RM.; Williams, A.W. Steel CM, Bird CC, et al: Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci USA 1994, 91, 6953-6957.
11. Evans, M.F.; Koreth, J.; Bakkenist, C.J.; Herrington, C.S.; McGee, J.O. Allelic deletion at 11q23.3-q25 is an early event in cervical neoplasia. Oncogene 1998, 16, 2557-2564.
12. Miyai, K.; Furugen, Y.; Matsumoto, T. et al. Loss of heterozygosity analysis in uterine cervical adenocarcinoma. Gynecol Oncol 2004, 94(1), 115-120.
13. Vo, Q.N.; Kim, W.J.; Cvitanovic. L.; Boudreau, D.A.; Ginzinger, D.G.; Brown, K.D. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 2004, 23, 9432-9437.
14. Kuramochi, M.; Fukuhara, H.; Nobukuni, T.; Kanbe, T.; Maruyama, T.; Ghosh, H.P.; Pletcher, M.; Isomura, M.; Onizuka, M.; Kitamura, T.; Sekiya, T.; Reeves, R.H.; Murakami, Y. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001, 27, 427-430.
15. Zhang, Z.; Huettner, P.C.; Nguyen, L.; Bidder, M.; Funk, M.C.; Li, J.; Rader, J.S. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 2006, 25, 5436-5445.
16. Sellar, G.C.; Watt, K.P.; Rabiasz, G.J.; Stronach, E.A.; Li, L.; Miller, E.P.; Massie, C.E.; Miller, J.; Contreras-Moreira, B.; Scott, D.; Brown, I.; Williams, A.R.; Bates, P.A.; Smyth, J.F.; Gabra, H. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003, 34, 337-343.
17. Matrisian, L.M.; Cunha, G.R.; Mohla, S. Epithelial-stromal interactions and tumor progression: meeting summaty and future directions. Cancer Res 2001, 61, 3844-3846.
18. Mueller, M.M.; Fusenig, N.E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4, 839-849.
19. Fukino, K.; Shen, L.; Matsumoto, S.; Morrison, C.D.; Mutter, G.L.; Eng, C. Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 2004, 64, 7231-7236.
20. Matsumoto, N.; Yoshida, T.; Yamashita, K.; Numata, Y.; Okayasu, I. Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. Br J Cancer 2003, 89, 707-712.
21. Fiegl, H.; Millinger, S.; Goebel, G.; Muller-Holzner, E.; Marth, C.; Laird, P.W.; Widschwendter, M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 2006, 66, 29-33.
22. Herman, J.G.; Graff J.R.; Myohanen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 1996, 93, 9821-9826.
23. Grunau, C.; Clark, S.J.; Rosenthal, A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001, 29, E65-E75.
24. Hachisuka, A.; Nakajima, O.; Yamazaki, T.; Sawada, J. Localization of opioid-binding cell adhesion molecule (OBCAM) in adult rat brain. Brain Res 1999, 842, 482-486.
25. Miyata, S.; Funatsu, N.; Matsunaga, W.; Kiyohara, T.; Sokawa, Y.; Maekawa, S. Expression of the IgLON cell adhesion molecules Kilon and OBCAM in hypothalamic magnocellular neurons. J Comp Neurol 2000, 424, 74-85.
26. Mei, F.C.; Young, T.W.; Liu, J.; Cheng, X. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J 2006, 20, 497-499.
27. Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. Nat Rev Cancer 2004 Feb;4(2), 143-153.
28. Schofield, P.R.; McFarland, K.C.; Hayflick, J.S.; Wilcox, J.N.; Cho, T.M.; Roy, S.; Lee, N.M.; Loh, H.H.; Seeburg, P.H. Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact. EMBO J 1989, 8, 489-495.
29. Levitt, P. A monoclonal antibody to limbic system neurons. Science 1984, 223, 299-301.
30. Struyk, A.F.; Canoll, P.D.; Wolfgang, M.J.; Rosen, C.L.; D'Eustachio, P.; Salzer, J.L. Cloning of neurotrimin defines a new subfamily of differentially expressed neural cell adhesion molecules. J Neurosci 1995, 15, 2141-2156.
31. Funatsu, N.; Miyata, S.; Kumanogoh, H.; Shigeta, M.; Hamada, K.; Endo, Y.; Sokawa, Y.; Maekawa, S. Characterization of a novel rat brain glycosylphosphatidylinositol-anchored protein (Kilon), a member of the IgLON cell adhesion molecule family. J Biol Chem 1999, 274, 8224-8230.
32. Chen, J.; Lui, W.O.; Vos, M.D.; Clark, G.J.; Takahashi, M.; Schoumans, J.; Khoo, S.K.; Petillo, D.; Lavery, T.; Sugimura, J.; Astuti, D.; Zhang, C.; Kagawa, S.; Maher, E.R.; Larsson, C.; Alberts, A.S.; Kanayama, H.O.; Teh, B.T. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 2003, 4, 405-413.
33. Ntougkos, E.; Rush, R.; Scott, D.; Frankenberg, T.; Gabra, H.; Smyth, J.F.; Sellar, G.C. The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates. Clin Cancer Res 2005, 11, 5764-5768.
34. Tisty, T.D.; Hein, P.W. Know thy neighbor: stromal cells can contribute oncogenic signals. Current opinion in genetic & development 2001, 11, 54-59.
35. Phillips, J.L.; Hayward, S.W.; Wang, Y.; Vasselli, J.; Pavlovich, C.; Padilla-Nash, H.; Pezullo, J.R.; Ghadimi, B.M.; Grossfeld, G.D.; Rivera, A.; Linehan, W.M.; Cunha, G.R.; Ried, T. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 2001, 61, 8143-8149.